
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiat... Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.44 | -3.45911949686 | 12.72 | 13.18 | 10.96 | 992542 | 11.92959548 | CS |
4 | -0.72 | -5.53846153846 | 13 | 15.25 | 10.96 | 605583 | 12.96535432 | CS |
12 | -1.03 | -7.73854244929 | 13.31 | 17.07 | 10.96 | 508799 | 13.68357354 | CS |
26 | 0.18 | 1.48760330579 | 12.1 | 17.7 | 10.96 | 519758 | 13.70345069 | CS |
52 | 1.13 | 10.134529148 | 11.15 | 17.7 | 7.97 | 595918 | 11.47604102 | CS |
156 | 5.9 | 92.4764890282 | 6.38 | 17.7 | 6.015 | 609237 | 9.89830762 | CS |
260 | 5.9 | 92.4764890282 | 6.38 | 17.7 | 6.015 | 609237 | 9.89830762 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions